Advertisement

Recurrent Cytogenetic Abnormalities in Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 1541)

Abstract

Characteristic chromosomal translocations are found to be associated with subtypes of B-cell non-Hodgkin lymphoma (NHL), for example t(8;14)(q24;q32) and Burkitt lymphoma, t(14;18)(q32;q21) and follicular lymphoma, and t(11;14)(q13;q32) in mantle cell lymphoma. Only few recurrent cytogenetic aberrations have been identified in the T-cell NHL and the best known is the ALK gene translocation t(2;5)(p23;q35) in anaplastic large cell lymphoma. Since lymph node or other tissue is seldom submitted for conventional cytogenetics study, alternative approaches for translocation detection are polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH). FISH is more sensitive than PCR in the detection of lymphoma translocations since directly labeled large FISH probes that span the translocation breakpoints are used. Although the recurrent chromosomal abnormalities in NHL are not completely sensitive and specific for disease entities, unlike the scenario in acute leukemia, cytogenetic and molecular genetic study is commonly used to aid lymphoma diagnosis and classification. Currently, the main clinical utility is in the employment of interphase FISH panels to predict disease aggressiveness to guide therapy, for example identification of double-hit lymphoma, or in prognostication, for example risk-stratification in chronic lymphocytic leukemia. The recent application of high-throughput sequencing to NHL not only advances the understanding of disease pathogenesis and classification, but allows the discovery of new drug targets, such as BRAF gene inhibition in hairy cell leukemia. Coupled with the increasing availability of novel molecular targeted therapeutic agents, the hope for the future is to translate the genetics and genomics information to achieve personalized medicine in NHL.

Key words

Cytogenetics Chromosomal translocation Non-Hodgkin lymphoma FISH PCR Diagnosis Classification Prognosis Molecular targeted therapy Personalized medicine 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood pii: blood-2016-01-643569Google Scholar
  2. 2.
    Belaud-Rotureau MA, Parrens M, Carrere N et al (2007) Interphase fluorescence in situ hybridization is more sensitive than BIOMED-2 polymerase chain reaction protocol in detecting IGH-BCL2 rearrangement in both fixed and frozen lymph node with follicular lymphoma. Hum Pathol 38(2):365–372CrossRefPubMedGoogle Scholar
  3. 3.
    Espinet B, Bellosillo B, Melero C et al (2008) FISH is better than BIOMED-2 PCR to detect IgH/BCL2 translocation in follicular lymphoma at diagnosis using paraffin-embedded tissue sections. Leuk Res 32(5):737–742CrossRefPubMedGoogle Scholar
  4. 4.
    van Dongen JJ, Langerak AW, Bruggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17(12):2257–2317CrossRefPubMedGoogle Scholar
  5. 5.
    Dohner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343(26):1910–1916CrossRefPubMedGoogle Scholar
  6. 6.
    Mayr C, Speicher MR, Kofler DM et al (2006) Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107(2):742–751CrossRefPubMedGoogle Scholar
  7. 7.
    Byrd JC, Smith L, Hackbarth ML et al (2003) Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 63(1):36–38PubMedGoogle Scholar
  8. 8.
    Garg R, Wierda W, Ferrajoli A et al (2012) The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer 118(14):3531–3537CrossRefPubMedGoogle Scholar
  9. 9.
    Zenz T, Eichhorst B, Busch R et al (2010) TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28(29):4473–4479CrossRefPubMedGoogle Scholar
  10. 10.
    Lozanski G, Heerema NA, Flinn IW et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103(9):3278–3281CrossRefPubMedGoogle Scholar
  11. 11.
    Pflug N, Bahlo J, Shanafelt TD et al (2014) Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 124(1):49–62CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Guo Y, Karube K, Kawano R et al (2005) Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. Leukemia 19(6):1058–1063CrossRefPubMedGoogle Scholar
  13. 13.
    Katzenberger T, Kalla J, Leich E et al (2009) A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 113(5):1053–1061CrossRefPubMedGoogle Scholar
  14. 14.
    Fonseca R, Blood EA, Oken MM et al (2002) Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99(10):3735–3741CrossRefPubMedGoogle Scholar
  15. 15.
    Treon SP, Cao Y, Xu L et al (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123(18):2791–2796CrossRefPubMedGoogle Scholar
  16. 16.
    Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364(24):2305–2315CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A et al (2001) Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357(9249):39–40CrossRefPubMedGoogle Scholar
  18. 18.
    Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937–1947CrossRefPubMedGoogle Scholar
  19. 19.
    Meyer PN, Fu K, Greiner TC et al (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29(2):200–207CrossRefPubMedGoogle Scholar
  20. 20.
    Scott DW, Wright GW, Williams PM et al (2014) Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123(8):1214–1217CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Boerma EG, Siebert R, Kluin PM et al (2009) Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. Leukemia 23(2):225–234CrossRefPubMedGoogle Scholar
  22. 22.
    So CC, Yung KH, Chu ML et al (2013) Diagnostic challenges in a case of B cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Int J Hematol 98(4):478–482CrossRefPubMedGoogle Scholar
  23. 23.
    Friedberg JW (2012) Double-hit diffuse large B-cell lymphoma. J Clin Oncol 30(28):3439–3443CrossRefPubMedGoogle Scholar
  24. 24.
    Tzankov A, Xu-Monette ZY, Gerhard M et al (2014) Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 27(7):958–971CrossRefPubMedGoogle Scholar
  25. 25.
    Pedersen MO, Gang AO, Poulsen TS et al (2014) MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol 92(1):42–48CrossRefPubMedGoogle Scholar
  26. 26.
    Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121(12):2253–2263CrossRefPubMedGoogle Scholar
  27. 27.
    Hu S, Xu-Monette ZY, Tzankov A et al (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121(20):4021–4031CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bruggemann M, White H, Gaulard P et al (2007) Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies. Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia 21(2):215–221CrossRefPubMedGoogle Scholar
  29. 29.
    Pascal V, Schleinitz N, Brunet C et al (2004) Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions. Eur J Immunol 34(10):2930–2940CrossRefPubMedGoogle Scholar
  30. 30.
    Morris SW, Kirstein MN, Valentine MB et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263(5151):1281–1284CrossRefPubMedGoogle Scholar
  31. 31.
    Savage KJ, Harris NL, Vose JM et al (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111(12):5496–5504CrossRefPubMedGoogle Scholar
  32. 32.
    Gesk S, Martin-Subero JI, Harder L et al (2003) Molecular cytogenetic detection of chromosomal breakpoints in T-cell receptor gene loci. Leukemia 17(4):738–745CrossRefPubMedGoogle Scholar
  33. 33.
    Feldman AL, Law M, Remstein ED et al (2009) Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 23(3):574–580CrossRefPubMedGoogle Scholar
  34. 34.
    Wada DA, Law ME, Hsi ED et al (2011) Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol 24(4):596–605CrossRefPubMedGoogle Scholar
  35. 35.
    Feldman AL, Dogan A, Smith DI et al (2011) Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 117(3):915–919CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Vasmatzis G, Johnson SH, Knudson RA et al (2012) Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 120(11):2280–2289CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Parrilla Castellar ER, Jaffe ES, Said JW et al (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124(9):1473–1480CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Streubel B, Vinatzer U, Willheim M et al (2006) Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 20(2):313–318CrossRefPubMedGoogle Scholar
  39. 39.
    Wlodarska I, Martin-Garcia N, Achten R et al (2002) Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 33(3):243–251CrossRefPubMedGoogle Scholar
  40. 40.
    Siu LL, Wong KF, Chan JK et al (1999) Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 155(5):1419–1425CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Siu LL, Chan V, Chan JK et al (2000) Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol 157(6):1803–1809CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Iqbal J, Kucuk C, Deleeuw RJ et al (2009) Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 23(6):1139–1151CrossRefPubMedGoogle Scholar
  43. 43.
    Huang Y, de RA, de LL et al (2010) Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 115(6):1226–1237CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Deleeuw RJ, Zettl A, Klinker E et al (2007) Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 132(5):1902–1911CrossRefPubMedGoogle Scholar
  45. 45.
    Cejkova P, Zettl A, Baumgartner AK et al (2005) Amplification of NOTCH1 and ABL1 gene loci is a frequent aberration in enteropathy-type T-cell lymphoma. Virchows Arch 446(4):416–420CrossRefPubMedGoogle Scholar
  46. 46.
    Yoo HY, Kim P, Kim WS et al. (2016) Frequent CTLA4-CD28 gene fusion in diverse types of T cell lymphoma. Haematologica. pii: haematol.2015.139253Google Scholar
  47. 47.
    Lohr JG, Stojanov P, Lawrence MS et al (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 109(10):3879–3884CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Wang L, Lawrence MS, Wan Y et al (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365(26):2497–2506CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Tiacci E, Park JH, De CL et al (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 373(18):1733–1747CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Department of PathologyHong Kong Sanatorium & HospitalHappy ValleyHong Kong

Personalised recommendations

Cite protocol

Buy options